Manufacturing Snag May Stall Portola's Bevyxxa Launch
Executive Summary
Company has priced its Factor Xa anticoagulant at $15 per capsule, on par with competitors, and is gearing up for a launch, but it first must resolve manufacturing issues with FDA as it scales up to commercial capacity.
You may also be interested in...
Garland Takes Helm Of Portola At A Crucial Time
Portola touts exec's commercial management experience with Genentech success stories Avastin and Tarceva.
Under The Radar: Potential Small Cap Takeover Targets
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will likely shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.